Nurix Therapeutics, Inc. reported financial results for the fiscal quarter ended August 31, 2026, and announced significant corporate updates regarding its clinical trials and collaborations. The company announced that it has dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial, a study comparing its drug candidate bexobrutideg to pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
The Phase 3 trial, known as NCT07516093, is a global, randomized study designed to evaluate the potential superiority of bexobrutideg. It will enroll approximately 620 patients whose disease has progressed following prior covalent BTK inhibitor therapy. Patients are randomized 1:1 to receive bexobrutideg 600 mg orally once daily or pirtobrutinib. The dual primary endpoints are objective response rate and progression-free survival, each assessed by an independent review committee.
In addition to the CLL trial, Nurix initiated recruiting for the Phase 1b/2 NX-5948-203 study. This study will evaluate bexobrutideg in combination with standard-of-care therapies, starting with a cohort evaluating the drug in combination with venetoclax.
On the financial front, Nurix reported revenue of $673.1 million for the quarter ended August 31, 2026, compared to $7.9 million in the same period the previous year. This increase was primarily driven by $653.2 million in license revenue from the collaboration with Roche and $10.0 million from a development milestone with Sanofi. The company also reported a net income of $549.8 million, or $4.73 per diluted share, for the quarter.
As of August 31, 2026, Nurix held $1.1 billion in cash, cash equivalents, and marketable securities. The company noted that this cash position provides a runway into the second half of 2029.
Regarding its partnership with Roche, the collaboration agreement designates development costs to be shared 40% by Nurix and 60% by Roche. Profits and losses in the United States are to be shared equally, while Nurix is eligible for tiered royalties on ex-U.S. sales.
Nurix also highlighted progress in its other clinical programs. Sanofi initiated a Phase 1 first-in-human clinical trial of an oral STAT6 degrader, triggering a $10 million milestone payment to Nurix. Furthermore, Nurix advanced its oral CBL-B inhibitor NX-1607 into Phase 1b expansion cohorts in microsatellite stable colorectal cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, and melanoma. The first patient was dosed in these expansion cohorts in September 2026.
